| Description | CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM against wild-type Bcr-Abl kinase and has anti-chronic myeloid leukemia (CML) activity. |
| Target activity | BCR-ABL (WT):21.3 nM |
| molecular weight | 525.04 |
| Molecular formula | C30H29ClN6O |
| CAS | 1388710-60-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Sun Y, et al. CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia. J Cancer. 2017 Aug 23;8(14):2774-2784. |